The bromodomain-containing proteins BRD9 and BRD7 are part of the human SWI/SNF chromatin-remodeling complexes BAF and PBAF. To date, no selective inhibitor for BRD7/9 has been reported despite its potential value as a biological tool or as a lead for future therapeutics. The quinolone-fused lactam is now reported as the first potent and selective inhibitor of the BRD7 and BRD9 bromodomains. Development of from a fragment hit was expedited through balancing structure-based inhibitor design and biophysical characterization against tractable chemical synthesis: Complexity-building nitro-Mannich/lactamization cascade processes allowed for early structure-activity relationship studies whereas an enantioselective organocatalytic nitro-Mannich reaction enabled the synthesis of the lead scaffold in enantioenriched form and on scale. This epigenetic probe was shown to inhibit the association of BRD7 and BRD9 to acetylated histones in vitro and in cells. Moreover, was used to demonstrate that BRD7/9 plays a role in regulating pro-inflammatory cytokine secretion.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871321PMC
http://dx.doi.org/10.1002/ange.201501394DOI Listing

Publication Analysis

Top Keywords

selective inhibitor
8
brd7 brd9
8
lp99 discovery
4
discovery synthesis
4
synthesis selective
4
selective brd7/9
4
brd7/9 bromodomain
4
inhibitor
4
bromodomain inhibitor
4
inhibitor bromodomain-containing
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!